Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2021 / Cilt: 74 - Sayı: 1

History of Vaccines and New Vaccine Strategies

Aşıların Tarihçesi ve Yeni Aşı Stratejileri

Pages
1–10
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, firstly, the developmental history of vaccine is mentioned briefly and new designs and technologies, distribution platforms and application methods in vaccine studies are explained.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Edward Jenner’s invention of vaccination in 1796 has been considered as one of the greatest accomplishments in the history of medicine and vaccination currently prevents 2 to 3 million deaths every year.
📊
Key Findings & Data:Despite this, more than 1,5 million people worldwide die from vaccine-preventable diseases each year.
💡
Conclusion & Impact:In this review, firstly, the developmental history of vaccine is mentioned briefly and new designs and technologies, distribution platforms and application methods in vaccine studies are explained.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Edward Jenner’s invention of vaccination in 1796 has been considered as one of the greatest accomplishments in the history of medicine and vaccination currently prevents 2 to 3 million deaths every year. Despite this, more than 1,5 million people worldwide die from vaccine-preventable diseases each year. In today’s increasingly mobile lifestyle, infectious diseases know no boundaries. The most recent example to this is the fact that severe acute respiratory syndrome coronavirus-2 which originated in Wuhan, China has become the reason of a global pandemic in a very short time. As well as these and similar infectious diseases that have emerged and have not yet been vaccinated, there are other infectious diseases that existing vaccine technologies cannot prevent despite their undeniable success and constitute a large share of mortality worldwide. Versatile vaccine development studies are being done against these diseases and fields of new delivery platforms, new adjuvants, new approaches in antigen presentation and new stable and efficient antigen production are being focused on. In this review, firstly, the developmental history of vaccine is mentioned briefly and new designs and technologies, distribution platforms and application methods in vaccine studies are explained.

Özet

1796 yılında Edward Jenner ile başlayan aşı serüveni, tıp tarihinin en büyük küresel başarılarından biri olarak kabul edilmekte ve günümüzde her yıl aşılama ile 2-3 milyon insanın hayatı kurtarılmaktadır. Bu gerçeğe rağmen yine her yıl tüm dünyada 1,5 milyondan fazla insan aşı ile önlenebilir hastalıklar yüzünden kaybedilmektedir. Günümüzde uluslararası hareketliliğin artışının bir getirisi olarak enfeksiyon hastalıkları sınır tanımamaktadır. Tüm dünya buna en son 2019 yılının sonunda Çin’in Wuhan kentinde ortaya çıkan şiddetli akut solunum sendromu koronavirüs-2 salgının kısa bir süre içerisinde pandemiye dönüşmesi ile tanık olmuştur. Bu ve benzeri yeni ortaya çıkan ve henüz aşısı olmayan enfeksiyon hastalıkları olduğu gibi, yadsınamaz başarılarına rağmen mevcut aşı teknolojilerinin önleyemediği ve dünya genelinde mortalitenin büyük payını oluşturan başka enfeksiyon hastalıkları da bulunmaktadır. Bu hastalıklara karşı çok yönlü aşı geliştirme çalışmaları sürdürülmekte ve temel olarak yeni dağıtım platformları, yeni adjuvanlar, antijen sunumunda yeni yaklaşımlar ve yeni kararlı, etkin antijen üretimi alanlarına yoğunlaşılmaktadır. Bu derlemede öncelikle aşının tarih boyunca gelişiminden kısaca bahsedilecek daha sonra aşı çalışmalarında yer alan yeni tasarım/teknolojilere, dağıtım platformlarına ve uygulama yollarına değinilecektir.

🔖

Cite This Article

KILIÇ, S. G., DOLAPÇI, İ. (2022). History of Vaccines and New Vaccine Strategies. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 74 - Sayı: 1, 1–10. https://ajindex.com/articles/443486

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005;18:21‐25
  2. World Health Organization. The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication, Geneva, December 1979;1-122
  3. Loomis RJ, Johnson PR. Emerging Vaccine Technologies. Vaccines (Basel). 2015;3:429‐447
  4. De Gregorio E, Rappuoli R. From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol. 2014;14:505-514
  5. Stanberry LR, Strugnell R. Vaccines of the future. Perspectives in Vaccinology. 2011;1:151‐199
  6. Bragazzi NL, Gianfredi V, Villarini M, et al. Vaccines Meet Big Data: Stateof- the-Art and Future Prospects. From the Classical 3Is (“Isolate-Inactivate- Inject”) Vaccinology 1.0 to Vaccinology 3.0, Vaccinomics, and Beyond: A Historical Overview. Front Public Health. 2018;6:62
  7. Rhee JH. Towards Vaccine 3.0: new era opened in vaccine research and industry. Clin Exp Vaccine Res. 2014;3:1-4
  8. Lepenies B, Yin J, Seeberger PH. Applications of synthetic carbohydrates to chemical biology. Curr Opin Chem Biol. 2010;14:404-411
  9. Pardee K, Slomovic S, Nguyen PQ, et al. Portable, On-Demand Biomolecular Manufacturing. Cell. 2016;167:248-259
  10. Türkiye EKMUD- Erişkin Bağışıklama Rehberi Türkiye Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Uzmanlık Derneği
  11. Güncelleme-2016
  12. Plotkin S, Orenstein W, Offit P. A short history of vaccines. In: Plotkin SA, Orenstein WA, Offit PA (Eds.) Plotkin’s Vaccines, sixthed, Saunders Elsevier, 2018:1-8
  13. Bagnoli F, Baudner B, Mishra RP, et al. Designing the next generation of vaccines for global public health. OMICS. 2011;15:545-566
  14. Seib KL, Zhao X, Rappuoli R. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin Microbiol Infect. 2012;18:109-116
  15. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3:445-450
  16. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287:1816-1820
  17. Mora M, Veggi D, Santini L, et al. Reverse vaccinology. Drug Discov Today. 2003;8:459-464
  18. Roldão A, Mellado MC, Castilho LR, et al. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010;9:1149-1176
  19. Akahata W, Yang ZY, Andersen H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates agai